Medication Use Sample Clauses

Medication Use. ‌ Medication use is expected to fall within the guidelines established for treating COPD [40]. Study participants will be asked to provide information regarding their use of four classes of medications, including bronchodilators (beta-agonists, anticholinergics, methylxanthines), corticosteroids, antibiotics, and anti-inflammatories (e.g. statins, roflumilast). Addition of new medications in these classes or alterations in dose over the course of the study will be tracked. Study participants will be requested to bring all medication containers with them to each follow-up visit.
Medication Use. Personal Use Only: I will take my medication exactly as prescribed and will not share, sell, or give it to anyone else. • No Unauthorized Dose Changes: I will not adjust my medication dosage without consulting my provider.
Medication Use. I understand that ISNAP will not refuse to enroll, limit the participation of, penalize, or otherwise discriminate against individuals with disabilities, including individuals with OUD, because such individuals use medications prescribed by a licensed practitioner as part of a medically necessary treatment plan. I understand I must refrain from eating or drinking any products containing alcohol, as well as, any over-the-counter medication containing any amount or kind of alcohol, ephedrine or diphenhydramine, certain herbal compounds, THC, or any other products that may cause me to produce a positive Urine Drug Screen to remain in compliance with IPRP. In addition, all forms of CBD Oil are prohibited even if the label states the product is “THC Free.” Kombucha Tea, Kratom, Whippets, Delta 8 and Delta 10 cartridges, poppy seeds, hand sanitizer, mouth wash nor the use of Vanilla Extract will be accepted as an excuse for a positive urine drug screen. If I am hospitalized or otherwise require any medical or dental treatment resulting in the prescribing of any mood- altering medication, I will immediately report this event to IPRP and my treatment provider(s). I will immediately send supporting documentation (i.e., discharge summary and/or prescriptions) to my IPRP Clinical Case Manager within 3 days/72 hours. I will upload any prescriptions I am taking into my Spectrum 360 app under the prescription tab. Further, I understand I may be removed from work if it is determined the positive test result is not due to ingestion of documented prescription medication and I must have a negative drug screen result before I may be allowed to return to work. I further understand and acknowledge the ingestion of some food or food supplements (i.e., herbs, poppy seeds) and over-the-counter medications (i.e., cough syrup, mouth wash, cold remedies) may result in a positive test. As such, no claim shall be made and IPRP will accept no claim that the presence of drugs in my specimen resulted from said items. A positive UDS may invoke consequences, including but not limited to, re-assessment by treatment provider, increased UDS frequency, an extension of my RMA, required attendance at a relapse-prevention group, dismissal from the program, or other requirements.
Medication Use. All drugs and medications administered to patients shall be those listed in the formulary developed by the Aurora Health Care Pharmacy & Therapeutics Committee and approved by the Medical Executive Committee. If a Practitioner prescribes a drug that is not on the Medical Center formulary, and the Aurora Health Care Pharmacy & Therapeutics Committee has made a decision to automatically substitute a formulary agent for that drug, the approved therapeutic alternative will be provided. If a Practitioner prescribes a drug that is not on the formulary, and the Aurora Health Care Pharmacy & Therapeutics Committee has not made a decision to automatically substitute a formulary agent, a pharmacist will contact the Practitioner to determine if a formulary agent can be substituted for the ordered drug. If the Practitioner feels the ordered drug is necessary, it will be obtained as a non- formulary item for the patient. Drugs for Institutional Review Board (IRB) approved clinical investigations that are not listed in the formulary shall be used only if in full accordance with the statements of principles involved in the use of investigational drugs in hospitals and all regulations of the Federal Food and Drug Administration, and only after approval by the Aurora Health Care Institutional Review Board (IRB). Policies for specific drugs will be generally based on specific concerns and will be subject to the review and approval of the Aurora Health Care Pharmacy & Therapeutics Committee. All other diagnostic orders (labs, x-ray, etc.) must be reviewed and renewed after three days, unless otherwise ordered by the attending Practitioner. Every Practitioner attending patients in the Medical Center shall comply with policies concerning drug use as developed by the Aurora Health Care Pharmacy & Therapeutics Committee. If an unacceptable abbreviation is contained in the Practitioner order, the pharmacist shall contact the Practitioner for clarification before carrying out the order in accordance with the Aurora Health Care Administrative Policy.

Related to Medication Use

  • Medication 1. ▇▇▇▇▇▇▇’s physician shall prescribe and monitor adequate dosage levels for each Client. 2. ▇▇▇▇▇▇▇’s physician shall not impose and/or limit dosage capitations for any prescribed medication for the treatment of opioid use disorder.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • System Use (a) An electronic site access system may be used on site, subject to the requirements of this statement. (b) The system operates via: (i) a facial recognition device; and (ii) an electronic gate. (c) The system will be installed at the access and egress point/s of the site and will only be utilised to identify presence on site. (d) The purpose for which the electronic site access system will be implemented is to ensure: (i) avoiding unauthorised access to site; (ii) confirmation and co-ordination of effort in emergency situations; and (iii) confirmation that all entrants to site have received a site specific induction; (e) The only personal data collected by the system is a site entrant’s: (i) image; (ii) first & last name; (iii) mobile phone number; (iv) email address; and (v) employer’s name. (the Collected Data) (f) The Collected Data will only be held or used for the purposes specified above, unless otherwise by consent or required by law. (g) The Employer will not use the electronic site access control system to verify who was on a site at a particular time for the purpose of: (i) evaluating whether a variation claim regarding labour costs made by a subcontractor can be substantiated; (ii) taking disciplinary action against an Employee, or assisting a subcontractor to take disciplinary action against its own employees, regarding their start and finish times; or (iii) otherwise generally tracking a worker’s movements whilst on the site.